Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat for anemia in lower-risk myelodysplastic syndromes
CTR20171146Phase 3Terminated
- Sponsor
- FaboGene
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of roxadustat in anaemia, myelodysplastic syndrome (MDS), sponsored by FaboGene. Started Nov 2017; status: terminated.
02
Drugs
roxadustat
03
Conditions
anaemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20171146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171146.